Literature DB >> 7851109

Is double data entry necessary? The CHART trials. CHART Steering Committee. Continuous, Hyperfractionated, Accelerated Radiotherapy.

D Gibson1, A J Harvey, V Everett, M K Parmar.   

Abstract

There is some controversy over the need for double data entry in clinical trials. In particular, does the number and types of errors identified with this approach justify the extra effort involved? We report the results of a study carried out to address this question. Our main outcome measure was the frequency and types of errors involved in the entry of data for the CHART (continuous, hyperfractionated, accelerated radiotherapy) trials. Data were reentered for a sample of 44 patients by a data manager other than the one making the initial entry. The second entry was then compared with the first entry. The error rate for the two entries combined was 14 per 10,000 data items (fields) (95% confidence interval 10, 19). The error rate for the initial entry alone was 15 per 10,000 fields (95% confidence interval 9.5, 22), and the vital/important error rate (defined as any error on a principal outcome measure or a major error on any other endpoint or variable) was 2.5 per 10,000 fields (95% confidence interval 0.68, 6.4). On this evidence double data entry is not performed for the CHART trials.

Entities:  

Mesh:

Year:  1994        PMID: 7851109     DOI: 10.1016/0197-2456(94)90005-1

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  9 in total

1.  Reducing errors from the electronic transcription of data collected on paper forms: a research data case study.

Authors:  Monika M Wahi; David V Parks; Robert C Skeate; Steven B Goldin
Journal:  J Am Med Inform Assoc       Date:  2008-02-28       Impact factor: 4.497

2.  Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database--UNC GOLD.

Authors:  Sarah A Gallagher; Angela B Smith; Jonathan E Matthews; Clarence W Potter; Michael E Woods; Mathew Raynor; Eric M Wallen; W Kimryn Rathmell; Young E Whang; William Y Kim; Paul A Godley; Ronald C Chen; Andrew Wang; Chaochen You; Daniel A Barocas; Raj S Pruthi; Matthew E Nielsen; Matthew I Milowsky
Journal:  Urol Oncol       Date:  2013-02-19       Impact factor: 3.498

3.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

4.  Growth in North American white children with neurofibromatosis 1 (NF1).

Authors:  J Szudek; P Birch; J M Friedman
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

5.  Comparing the accuracy and speed of four data-checking methods.

Authors:  Kimberly A Barchard; Andrew J Freeman; Elizabeth Ochoa; Amber K Stephens
Journal:  Behav Res Methods       Date:  2020-02

6.  The Strathclyde Evaluation of Children's Active Travel (SE-CAT): study rationale and methods.

Authors:  David McMinn; David A Rowe; Shemane Murtagh; Norah M Nelson
Journal:  BMC Public Health       Date:  2011-12-30       Impact factor: 3.295

7.  Quality control and data-handling in multicentre studies: the case of the Multicentre Project for Tuberculosis Research.

Authors:  T Caloto
Journal:  BMC Med Res Methodol       Date:  2001-12-21       Impact factor: 4.615

8.  Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.

Authors:  Andrew Embleton-Thirsk; Elizabeth Deane; Stephen Townsend; Laura Farrelly; Babasola Popoola; Judith Parker; Gordon Rustin; Matthew Sydes; Mahesh Parmar; Jonathan Ledermann; Richard Kaplan
Journal:  Clin Trials       Date:  2019-07-26       Impact factor: 2.486

9.  Making a distinction between data cleaning and central monitoring in clinical trials.

Authors:  Sharon B Love; Victoria Yorke-Edwards; Carlos Diaz-Montana; Macey L Murray; Lindsey Masters; Michelle Gabriel; Nicola Joffe; Matthew R Sydes
Journal:  Clin Trials       Date:  2021-03-02       Impact factor: 2.486

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.